Davunetide (NAP/AL-108) vs FGL Peptide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Davunetide (NAP/AL-108) or FGL Peptide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Davunetide (NAP/AL-108) and FGL Peptide?
Davunetide provides a known-negative human dataset useful for understanding NAP biology; FGL peptide has never been in humans and carries a theoretical FGFR1-mediated oncogenic risk.
Evidence Comparison
Davunetide: Phase 2/3 in PSP (Boxer 2014, Lancet Neurol), failed primary endpoint - definitive negative human data. FGL peptide: NCAM-derived, rodent studies only, FGFR1 oncogene concern. Davunetide has stronger evidence by virtue of human PK/PD data, despite the negative efficacy result.
Evidence Context Favoring Davunetide (NAP/AL-108)
Research into NAP/ADNF neuroprotection with access to human trial pharmacology data.
Evidence Context Favoring FGL Peptide
NCAM-mediated neural plasticity research in animal models, accepting the FGFR1 safety caveat and absence of human data.
Side-by-Side Snapshot
| Evidence grade | Davunetide (NAP/AL-108): Level C FGL Peptide: Level D |
|---|---|
| Research status | Davunetide (NAP/AL-108): Phase 2 FGL Peptide: Preclinical |
| Primary category | Davunetide (NAP/AL-108): Cognitive & Nootropic FGL Peptide: Cognitive & Nootropic |
| Cited studies | Davunetide (NAP/AL-108): 3 FGL Peptide: 3 |